Abstract
A dose-dependent cutaneous leukocytoclastic vasculitis developed in a 34 year old man who was given amiodarone for supraventricular tachycardias resistant to other drugs. This adverse reaction disappeared within 2 weeks after discontinuation of amiodarone despite its very long half-life of 52 days in this patient. During previous treatment periods with amiodarone, the patient had experienced photosensitivity and dose-dependent polyserositis. Since high doses of amiodarone have been recently proposed for the treatment of resistant cardiac arrhythmias, dose-dependent adverse effects as described here may be encountered with increasing frequency.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Braverman I. M., Yen A. Demonstration of immune complexes in spontaneous and histamine-induced lesions and in normal skin of patients with leukocytoclastic angitis. J Invest Dermatol. 1975 Feb;64(2):105–112. doi: 10.1111/1523-1747.ep12510321. [DOI] [PubMed] [Google Scholar]
- Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981 Sep 3;305(10):539–545. doi: 10.1056/NEJM198109033051002. [DOI] [PubMed] [Google Scholar]
- Jonckheer M. H., Blockx P., Kaivers R., Wyffels G. Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone. Acta Cardiol. 1973;28(2):192–200. [PubMed] [Google Scholar]
- Kramer M. S., Leventhal J. M., Hutchinson T. A., Feinstein A. R. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979 Aug 17;242(7):623–632. [PubMed] [Google Scholar]
- Meier C., Kauer B., Müller U., Ludin H. P. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol. 1979 Jan 5;220(4):231–239. doi: 10.1007/BF00314147. [DOI] [PubMed] [Google Scholar]
- Rotmensch H. H., Liron M., Tupilski M., Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J. 1980 Sep;100(3):412–413. doi: 10.1016/0002-8703(80)90165-9. [DOI] [PubMed] [Google Scholar]
- Sams W. M., Jr, Thorne E. G., Small P., Mass M. F., McIntosh R. M., Stanford R. E. Leukocytoclastic vasculitis. Arch Dermatol. 1976 Feb;112(2):219–226. [PubMed] [Google Scholar]
- Stäubli M., Bircher J., Galeazzi R. L., Remund H., Studer H. Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol. 1983;24(4):485–494. doi: 10.1007/BF00609891. [DOI] [PubMed] [Google Scholar]
- Tartini R., Kappenberger L., Steinbrunn W., Meyer U. A. Dangerous interaction between amiodarone and quinidine. Lancet. 1982 Jun 12;1(8285):1327–1329. doi: 10.1016/s0140-6736(82)92400-x. [DOI] [PubMed] [Google Scholar]
- Wimpfheimer C., Stäubli M., Schädelin J., Studer H. Prednisone in amiodarone-induced thyrotoxicosis. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1835–1836. doi: 10.1136/bmj.284.6332.1835-a. [DOI] [PMC free article] [PubMed] [Google Scholar]